We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Federal efforts to protect the drug supply chain continue to bear fruit, with the FDA’s Office of Criminal Investigations announcing criminal charges for another counterfeit operation. Read More
Patent cases involving payments by brand drugmakers to delay generic competition have dropped 27 percent following a 2013 challenge to the practice, according to the Federal Trade Commission. Read More
Boehringer Ingelheim has to hand over settlement papers to the FTC after the U.S. Supreme Court rejected the company’s assertion that the documents are protected communications. Read More
Sharp price spikes for some orphan generics may be getting all of the attention today, but they have little real impact on overall prescription drug prices. Read More
Turing Pharmaceuticals and Valeant Pharmaceuticals lined “their pockets at the expense of some of the most vulnerable families in our nation,” House Oversight Committee Ranking Member Elijah Cummings (D-Md.) says in a memo to committee members. Read More
Novartis now faces competition to its top-seller Gleevec, a treatment for chronic myeloid leukemia, as Sun Pharma launched its copycat version in the U.S. Monday. Read More
The war on high pharmaceutical prices continues, with PBM Express Scripts taking aim at what it calls an excessive price jump for Valeant Pharmaceuticals’ diabetes drug Glumetza. Read More
Sharp price spikes for some orphan generics may be getting all of the attention today, but they have little real impact on overall prescription drug prices. Read More
After serving as Gilead Sciences’ CEO for 20 years, John C. Martin announced Friday that he is stepping down and will assume the role of executive chairman of the company. Read More